Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer

Gaurav Goel, Aman Chauhan, Peter J. Hosein

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Angiogenesis is a multistep process that plays a key role in cancer growth and metastases. It is mediated through multiple vascular endothelial growth factor receptors (VEGFRs) and their ligands. The expression of VEGFR-2 is upregulated in tumor endothelial cells, and it is considered to be the primary receptor driving malignant angiogenesis. Ramucirumab (IMC-1121B, LY3009806) is a fully human monoclonal antibody that directly binds to VEGFR-2 with high affinity and specificity. It is also the most recent addition to our armamentarium of anti-angiogenic drugs approved for the treatment of metastatic colorectal cancer (CRC). The aim of this review is to summarize the pre-clinical and clinical development of ramucirumab and discuss its place in the current treatment paradigm for metastatic CRC.

Original languageEnglish (US)
Pages (from-to)232-240
Number of pages9
JournalCurrent Colorectal Cancer Reports
Issue number5
StatePublished - Oct 1 2016
Externally publishedYes


  • Angiogenesis
  • Colorectal cancer
  • IMC-1121B
  • Monoclonal antibody
  • Ramucirumab
  • VEGF
  • VEGFR-2
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology


Dive into the research topics of 'Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

Cite this